KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Baxter International (BAX) Research & Development (2016 - 2024)

Baxter International (BAX) has disclosed Research & Development for 16 consecutive years, with $176.0 million as the latest value for Q1 2024.

  • On a quarterly basis, Research & Development rose 7.32% to $176.0 million in Q1 2024 year-over-year; TTM through Mar 2024 was $530.0 million, a 13.98% increase, with the full-year FY2025 number at $518.0 million, down 12.2% from a year prior.
  • Research & Development was $176.0 million for Q1 2024 at Baxter International, up from $23.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $176.0 million in Q1 2024 to a low of $2.0 million in Q4 2022.
  • A 5-year average of $129.2 million and a median of $139.0 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 98.52% in 2022, then skyrocketed 1050.0% in 2023.
  • Baxter International's Research & Development stood at $135.0 million in 2020, then changed by 0.0% to $135.0 million in 2021, then plummeted by 98.52% to $2.0 million in 2022, then surged by 1050.0% to $23.0 million in 2023, then surged by 665.22% to $176.0 million in 2024.
  • Per Business Quant, the three most recent readings for BAX's Research & Development are $176.0 million (Q1 2024), $23.0 million (Q4 2023), and $166.0 million (Q3 2023).